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Abstract 
From several animal studies and clinical observations it became evident that at target tissue level 1,25dihydroxyvitamin D, 
(1,25-(OH),D,) and parathyroid hormone (PTH) must act in an interrelated manner. In the present study we examined the interaction 
between 1,25-(OH),D, and PTH in the target cell of these hormones in bone, the osteoblast. In addition we studied the role of 
PTH-activated signal pathways. The three osteoblastic cell lines UMR 106, ROS 17/2.8 and MG-63 were used as model systems. In 
UMR 106 cells 1,25-(OH),D, and PTH caused a synergistic up-regulation of the vitamin D receptor (VDR) which was accompanied by a 
synergistic induction of VDR mRNA expression whereas in both ROS 17/2.8 and MG-63 cells no interaction was observed. In UMR 
106 cells the effect of PTH on homologous up-regulation of VDR could be mimicked by the CAMP agonist forskolin and by 
dibutyrylic-CAMP. Phorbol ester activation of protein kinase C reduced basal as well as 1,25-(OH),D,-induced up-regulation of VDR. 
1,25-(OH),D, induced 24-hydroxylase activity in UMR 106 and MC 63 cells and, in contrast to VDR regulation, in both cell lines PTH 
and 1,25-(OH&D, synergistically induce 24-hydroxylase activity. Similar to VDR regulation the effect of PTH was mimicked by 
activation of CAMP production whereas protein kinase C activation reduced the induction by 1,25-(OH),D,. Finally, we examined the 
interaction with respect to osteocalcin synthesis. In ROS 17/2X and MG-63 cells 1,25-(OH),D, stimulated osteocalcin production. In 
ROS 17/2.8 cells PTH as well as stimulation of CAMP production by forskolin enhanced 1,25-(OH),D,-induced osteocalcin production 
whereas, as we have shown previously, activation of protein kinase C does not change 1,25-(OH)aD,-stimulated osteocalcin production. 
In MG-63 cells neither PTH nor forskolin significantly changed 1,25-(OH),D, induction of osteocalcin synthesis. From the present study 
it can be concluded that indeed at target cell level 1,25-(OH),D, and PTH act in a coordinated manner. On basis of the potentiation of 
1,25-(OH&D, action by PTH in osteoblasts together with the previously reported inhibition of PTH-stimulated CAMP production by 
1,25-(OH),D, we postulate a negative feedback-loop at target cell level. The activation of the CAMP pathway results in an enhancement 
of the 1,25-(OH),D, action whereas the protein kinase C pathway attenuates the 1,25-(OH),D, action. Finally, the present study provides 
a basis for the indications from in vivo observations about an interrelated action of 1,25-(OH),D, and PTH at the target cell. More 
generally it demonstrates on the basis of analyses of endogenous cellular responses evidence for an interplay between receptor-activated 
pathways of peptide and steroid hormones. 
Keywords: Vitamin D,; Parathyroid hormone; Bone: Osteoblast; Interaction; Second messenger 
1. Introduction 
1,25-Dihydroxyvitamin D, (1,25(OH), D,) and parathy- 
roid hormone (PTH) are two important hormones involved 
in the regulation of calcium homeostasis. From in vitro as 
well as in vivo studies evidence has been obtained demon- 
strating that these calciotropic hormones mutually regulate 
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each others synthesis and/or secretion. Their actions on 
the kidneys and parathyroids are regulated via a feed-back 
loop. PTH has been shown to induce an increase in renal 
1 cu-hydroxylase activity [1,2] and can also modulate 
1,25(OH),D, receptor (VDR) level in kidney [3]. In re- 
turn, 1,25(OH),D, lowers preproPTH mRNA levels [4,5] 
with a subsequent reduction in PTH secretion [6]. More- 
over, at osteoblast level several interactions have been 
observed. 1,25-(OH),D, reduces PTH-stimulated CAMP 
production [7,8] and PTH increases the VDR number [9] 
via an increase in VDR mRNA in UMR 106 cells [lo] 
0167-4889/96/$15.00 0 1996 Elsevier Science B.V. All rights reserved 
PII SO167-4889(96)00016-X 
56 J.P.T.M. t’an Leeuwen et d./Biochimica et Biophysicu Acta 1312 (1996155-62 
whereas a decrease in VDR was observed in ROS 17/2.8 
cells [I 11. 
In calcium homeostasis one of the target tissues for 
1,25(OH),D, and PTH is bone. For both hormones the 
receptors in bone are located on the osteoblast [12-141. 
Although 1,25(OH), D, receptors have been demonstrated 
in osteoclast progenitors [15] it is generally accepted that 
1,25(OH)?D, and PTH stimulate osteoclastic bone resorp- 
tion via a primary action on the osteoblast [ 161. At the 
tissue level interaction between vitamin D and PTH with 
respect to bone resorption was already suggested by Raisz 
in 1965 [17]. This was supported by in vivo studies which 
indicated that PTH and 1,25(OH),D, work in concert to 
mobilize bone mineral [18]. In a recent study we have 
demonstrated that pretreatment with PTH potentiates the 
1,25-(OH),D,-stimulated bone resorption in vitro [ 191. 
Besides the above mentioned indications for interac- 
tions between 1,25(OH),D, and PTH the background of 
the current study is formed by the knowledge of the 
cascade of events following a serum calcium disturbance. 
First response, within minutes, to a reduction in serum 
calcium concentration is a rise in PTH levels. Subse- 
quently, within hours, stimulation of renal 25(OH)D,-1 (Y- 
hydroxylase by PTH occurs which eventually results in an 
increased serum 1,25(OH), D, concentration [I I. Under 
these circumstances also bone will first be exposed to 
increased PTH levels before increased 1,25(OH),D, lev- 
els. However, a positive interaction between PTH and 
1,25-(OH),D, in osteoblasts might also result in an early 
enhancement of 1,25-(OH), D, responses independent of 
an increase in 1,25-(OH),D, concentration. Moreover, the 
observation that in patients with hypoparathyroidism nor- 
mally higher doses of 1,25-(OH),D, than produced en- 
dogenously under normal circumstances are needed to 
obtain normocalcemia suggests a relative resistance to 
1,25-(OH&D, in the absence of PTH [20,21]. 
In the present study we focussed on the interaction 
between PTH and 1,25-(OH),D, in the regulation of bone 
cell function by using three different osteoblastic cell lines: 
UMR 106, ROS 17/2.8 and MG-63. In addition the role 
of intracellular signal pathways known to be activated by 
PTH have been studied with respect to interaction with 
1,25-(OH),D,. 
2. Materials and methods 
2. I. Materials 
Bovine fragment l-34 PTH (bPTH(l-34), dibutyryl 
CAMP (Bt,cAMP), phorbol 12-myristate 13-acetate (PMA) 
were obtained from Sigma (St. Louis, MO, USA). Forskolin 
was purchased from Calbiochem-Behring (La Jolla, CA, 
USA) and Bay K 8644 was a generous gift of Dr. Garthoff 
of Bayer AG (Wuppertal, Germany). [23,24- 3Hl- 1,25- 
(OH), D, ( 105 Ci/mmol), [26,27- 3H]25-(OH)D3 (18.7 1 
Ci/mmol), and [ 32 P]dATP were obtained from Amersham 
(Aylesbury, Buckinghamshire, UK). Non-radioactive 
1,25(OH), D, and 24,25(0H), D, were generously pro- 
vided by LEO Pharmaceuticals, Weesp, The Netherlands. 
GeneScreen filters were from New England Nuclear (Bos- 
ton, MA, USA) and X-AR x-ray films from Eastman 
Kodak (Rochester, NY, USA). The VDR cDNA probe was 
generously provided by Dr. J.W. Pike. Fetal calf serum 
(FCS), a-Minimum Essential Medium ( CY MEM), peni- 
cillin, streptomycin, and glutamine were purchased from 
Flow Laboratories (Rockville, NY, USA). Chromsphere SI 
HPLC columns were from Chrompack International (Mid- 
delburg, The Netherlands). 
2.2. Cell culture 
UMR 106, ROS 17/2.8 (rat), and MG-63 (human) cells 
were seeded at 50000 cells/cm2 and cultured for 24 h 
with aMEM supplemented with 2 mM glutamine, 0.1% 
glucose, 100 U/ml penicillin, 100 pg/ml streptomycin, 
and 10% FCS. Next, medium was replaced by (uMEM 
with 2% charcoal-treated FCS and cells were cultured for a 
24 h or 48 h period during which the cells reached 
confluence. During this period, cells were incubated with 
the agents to be tested. 
2.3. Preparation of cell extracts and I,25(OH), D, bind- 
ing assay 
For single point assays, conditions were employed which 
were previously shown to provide valid estimates of total 
receptor content in cytosolic extracts [22]. The cells were 
incubated and cultured as described above. Before prepara- 
tion of cell extracts, media were aspirated and the cells 
were incubated for an additional 2 h with MEM + 10% 
FCS at 37°C to promote dissociation of hormone from the 
receptor. Next, the cell pellet was extracted on ice in a 
hypertonic buffer consisting of 300 mM KCl, 10 mM 
Tris-HCl (pH 7.4), 1 mM EDTA, 5 mM dithiothreitol, 10 
mM sodium molybdate and 0.1% Triton X- 100. High-speed 
supematants were obtained and 200 ~1 aliquots were 
incubated overnight at 0°C with 0.5 nM [ 3H]l ,25(OH),D, 
in the absence or presence of a 200-fold molar excess of 
unlabeled hormone. Receptor bound 1,25(OH), D, was 
separated from unbound sterol by charcoal adsorption [231. 
2.4. 24-Hydroxylase acitivity 
After incubation with 1,25-(OH),D, in the absence or 
presence of the other agents the cells were washed for 2 h 
with (Y-MEM + 2% BSA followed by an incubation for 1 
h with 10 nM [ 3H]25(OH)D3 in the presence of 0.1% 
BSA. Subsequently, the formation of 24,25(OH),D, was 
assessed with HPLC using a Silica column and a mobile 
phase of hexane/isopropanol/methanol (95:4: 1) to elute 
the metabolites as described previously [24]. 
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2.5. Osteocalcin measurements 2.6. RNA isolation and hybridization 
Osteocalcin measurement in medium of MG-63 cells 
was performed by use of the INCSTAR (Stillwater, MN, 
USA) RIA kit for osteocalcin. Before measurements, 
medium was freeze-dried and reconstituted in assay buffer, 
so that medium was concentrated 6-fold. Osteocalcin mea- 
surements in cells and medium of ROS 17/2.8 cells were 
performed according to the method described by Ver- 
haeghe et al. [25]. 
RNA isolation was performed according to the method 
of Chomszinski [26] and used for dot blot analysis. Blots 
were prehybridized for 2 h at 42°C in a buffer containing 
50% formamide, 0.2% SDS, 1 X Denhardt’s solution, 5 X 
SSC (1 x SSC = 150 mM NaCl and 15 mM Na citrate, pH 
7.0), 20 mM NaH,PO,, 6% dextran sulfate, 1 pg/ml 
herring sperm DNA and then hybridized for 16-24 h at 
42°C with “‘P-labeled VDR cDNA probe (1.7 kb). Next, 
after washing the filters several times they were exposed to 
X-ray films. For normalization filters were washed for 2 h 
at 65°C with 5 mM Tris-HCl (pH 8.0), 0.2 mM Na,EDTA 
(pH 8.01, 0.05% sodium pyrophosphate and 0.1 X 
Denhardt’s solution and rehybridized with a 0.8 kb human 
GAPDH fragment. 
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2.7. Protein and DNA measurement 
The protein concentration was measured according to 
the method of Bradford [27]. DNA content was assessed 
by the fluorimetric method of Johnson-Wint and Hollis 
[281. 
2.8. Data analyses 
Interactions between various drugs were evaluated us- 
ing analysis of variance for two-way design. This statisti- 
cal method enables evaluation of the significance of inter- 
action between different factors and is applied in all cases 
when two drugs are added together. Other statistical analy- 
ses were performed using Student’s t-test. 
3. Results 
3.1. Effect of 1,25-(OH),D, in combination with PTH on 
the VDR 
Firstly, we studied the effect of 1,25-(OH),D, in com- 
bination with PTH on the VDR in UMR 106 cells. Both 
Fig. 1. Effect of F’TH on 1,25-(OH),D,-induced up-regulation of VDR 
and VDR mRNA expression in UMR 106 cells. (A) Cells were incubated 
for 4 h with several concentrations 1,25-(OH),D, and 10 nM PTH. (B) 
Time-course of coordinated up-regulation of VDR by 1.25(OH),D, and 
P’TH in UMR 106 cells. Cells were incubated for various periods of time 
with 10 nM 1,25-(OH&D, and 10 nM PTH. VDR content was assayed in 
cytosolic extracts as described in Section 2. Data are expressed as fmol of 
[3H11,25-(OH),D, bound per mg protein +S.D. for at least four differ- 
ent cultures. (C) Effect on VDR mRNA expression. Cells were incubated 
for 4 h with several concentrations 1,25-(OH&D, and 10 nM RTH. Next, 
total RNA was isolated and used for dot-blot analysis. The autoradiogram 
was quantitated by densitometric scanning and the ratio of VDR/GARDH 
is expressed as experiment over control. * P < 0.05 and * * P < 0.001 
versus no addition of 1.25-(OH),D, and F’TH; # P < 0.005 calculated as 
the the significance of interaction between 1.25(OH), D, and FTH. 
58 J.P.T.M. can Leeuwen et al. / Biochimica et Biophysics Acta I312 (199615542 
1,25-(OH),D, and PTH cause an up-regulation in these 
cells with a different magnitude and time-course (Refs. 
[9,19], and Fig. I). Incubation for 4 h of 10 nM PTH 
together with a dose-range of 1,25-(OH),D, resulted in 
synergistic up-regulation of the VDR in UMR 106 cells 
(Fig. IA). Time-course studies revealed that the effect of 
PTH alone was transient whereas up to 24 h synergistic 
up-regulation of VDR by I,25(OH),D, and PTH was 
observed (Fig. 1B). Next, we examined the effect of 
coincubation on the VDR mRNA level in UMR 106 cells. 
As shown in Fig. IC, coincubation with 1,25-(OH),D, 
and PTH also synergistically induced VDR mRNA expres- 
sion. 
Secondly, the combined actions of 1,25-(OH)2D, and 
PTH on VDR level in ROS 17/2.8 and MG 63 cells were 
studied. As in UMR 106 cells 1,25-(OH),D, caused up- 
regulation of VDR in ROS 17/2.8 cells whereas 10 nM 
PTH did not affect VDR in these cells (Fig. 2). Both 
1,25-(OH),D, and PTH had no effect on VDR in MG 63 
cells (Fig. 2). In contrast to UMR 106 cells, in ROS 
17/2.8 as well as MG 63 cells 1,25-(OH),D, and PTH 
had no synergistic effect on VDR (Fig. 2). 
3.2. lZfect of second messengers on homologous up-regu- 
lation of VDR 
PTH has been shown to activate several intracellular 
signal pathways [29-341. In order to assess a role for 
CAMP in the potentiation of homologous up-regulation of 
VDR we tried in UMR 106 cells to mimic the PTH effect 
by the CAMP agonist forskolin. As shown in Fig. 3, 
forskolin (10 PM) and 1,25-(OH), D, synergistically up- 
regulate VDR level in UMR 106 cells. With the CAMP 
analogue Bt,cAMP a similar effect was observed (Fig. 
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Fig. 2. Effect of PTH and 1,25-(OH),D, on VDR level in ROS 17/2.8 
and MG-63 cells. Cells were cultured as described in Section 2 and after 
incubation with PTH and I,25(OH), D, the VDR content was assayed in 
cytosolic extracts. For reasons of clarity data are expressed as treatment 
over control ROS 17/2.8 or control MG 63 cells. Control VDR levels 
were 42.89f 1.57 and 12.57kO.89 fmol/mg protein for ROS 17/2.8 
and MG 63 cells, respectively. * P < 0.001 versus no addition of 
1,25-(OH), D, and PTH. 
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Fig. 3. Effect of forskolin on 1,25-(OH),D,-induced up-regulation of 
VDR in UMR 106 cells. Cells were incubated for 4 h with several 
concentrations 1,25-(OH&D, and 1 PM forskolin. Next, the VDR 
content was assayed in cytosolic extracts as described in Section 2. Data 
are expressed as fmol of [‘H]1,25-(OH&D3 bound per mg protein f S.D. 
for at least four different cultures. * P < 0.01 and * * P < 0.001 versus 
no addition of 1,25-(OH&D, and forskolin; # P < 0.05 and ## P < 
0.005 calculated as the the significance of interaction between 1,25- 
(OH),D, and forskolin. 
4A). Calcium has been shown to be involved in the 
heterologous up-regulation of VDR by PTH [35]. How- 
ever, increasing intracellular calcium concentration with 
the calcium agonist BAY K 8644 did not result in potentia- 
tion of 1,25-(OH)2D,-induced up-regulation of VDR (Fig. 
4A). Recently, we have shown that activation of protein 
kinase C by phorbol ester treatment for 4 h caused down- 
regulation of VDR [36]. Addition of the phorbol ester 
PMA together with 1,2.5-(OH),D, resulted also in a reduc- 
tion of homologous up-regulation of VDR (Fig. 4B). 
3.3. Regulation of 24-hydroqlase activity by 1,25-(OH), D, 
and PTH 
In most of the tissues 1,25-(OH),D, induces 24-hy- 
droxylase activity. This enzyme initiates a catabolic cas- 
cade (C24-oxidation pathway) for the side-chain oxidation, 
cleavage and ultimate metabolic elimination of 1,25- 
(OH),D, and its precursor 25(OH)D, [37]. Also in UMR 
106 and MG-63 cells (Fig. 5A and B) but not ROS 17/2.8 
cells [38] 1,25-(OH),D, is a potent inducer of 24-hydrox- 
ylase activity. After 1 h 1,25-(OH),D, caused a strong 
induction of 24-hydroxylase activity whereas 10 nM PTH 
alone was not effective (Fig. 5A and B). However, when 
both UMR 106 and MG-63 cells were treated by 1,25- 
(OH),D, together with 10 nM PTH a synergistic induction 
of 24-hydroxylase activity was observed (Fig. 5A and B). 
3.4. Effect of CAMP and protein kinase C on induction of 
24-hydroxylase activity 
As in both UMR 106 and MG-63 cells a synergistic 
induction of 24-hydroxylase activity by PTH and 1,25- 
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(OH),D, was observed the role of CAMP and protein 
kinase C was further examined in UMR 106 cells. Cells 
were incubated for 1 h with 1,25-(OH),D, in the absence 
and presence of 1 PM forskolin or 100 nM PMA. Activa- 
tion of the CAMP pathway by forskolin resulted in poten- 
tiation of 1,25-(OH&D,-induced 24-hydroxylase activity. 
In contrast, activation of protein kinase C by PMA caused 
reduction of 1,25-(OH),D,-induced 24-hydroxylase activ- 
ity (Fig. 6). Comparison of Fig. 5A and Fig. 6 demon- 
strates that 10 nM PTH was more potent than 1 PM 
forskolin. This is in accordance with their potencies to 
stimulate CAMP production: Control: 0.77 + 0.08, 10 nM 
PTH: 71.95 k 4.37, and 1 /_LM forskolin: 4.83 f 0.28 pmol 
CAMP. 
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Fig. 4. Effect of (A) the CAMP analogue Bt,cAMP, the calcium agonist 
BAY K 8644, and (B) the activator of protein kinase C PMA on 
1,25-(OH)zDs-induced up-regulation of VDR in UMR 106 cells. Cells 
were incubated for 4 h with 1,25-(OH&D, in the presence or absence of 
Bt,cAMP, BAY K 8644 or PMA. Next, VDR content was assayed in 
cytosolic extracts as described in Section 2. Data are expresed as fmol of 
[3H]1,25-(OH),D, bound per mg protein + S.D. for at least four differ- 
ent cultures. * P < 0.025 and * * P < 0.005 versus no addition of 
1,25-(OH),D, or any of the other compounds: # P < 0.05 and ## 
P < 0.001 calculated as the the significance of interaction between 1,25- 
(OH),D, and any of the other compounds. 
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Fig. 5. Effect of PTH on 1,25-(OH),D3-induced 24.hydroxylase activity 
in (A) UMR 106 cells and (B) MG-63 cells. Cells were incubated for 1 h 
with several concentrations 1,25-(OH&D, and 10 nM PTH followed by 
an incubation for 1 h with 10 nM [3H]25-(OH)D, as substrate. Next, after 
a 2 h wash the 25-(OH)D, metabolites were extracted and analyzed by 
HPLC. Data are expressed as fmol 24,25-(OH&D, formed kS.D. of at 
least two independent cultures. * P < 0.001 versus no addition of 
1,25-(OH),D, and PTH; # P < 0.005 and ## P < 0.001 calculated as 
significance of interaction between 1,25-(OH)2DT and PTH. 
3.5. Effect of I,25(OH), D, and PTH on osteocalcin 
synthesis 
In contrast to UMR 106 cells, both MG-63 and ROS 
17/2.8 cells synthesize osteocalcin which is stimulated by 
1,25-(OH),D,. In MG-63 cells PTH did not affect 1,25- 
(OH),D,-stimulated osteocalcin production whereas in 
ROS 17/2.8 cells cotreatment with PTH enhanced 1,25- 
(OH),D,-stimulated osteocalcin production (Fig. 7A and 
B). PTH by itself did not induce osteocalcin production in 
both cell lines. Activation of the CAMP pathway with 
forskolin mimicked the potentiating effect of PTH in ROS 
17/2.8 cells (Fig. 7B) and in MG-63 cells forkolin did not 
significantly change 1,25-(OH), D,-stimulated osteocalcin 
production (Fig. 7A). We have previously shown that 
activation of protein kinase C by phorbol esters did not 
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Fig. 6. Effect of forskolin and PMA on 1.25.(OH&D,-induced 24-hy- 
droxylase activity in UMR 106 cells. Cells were incubated for 1 h with 
several concentrations 1,25-(OH), D, and I PM forskolin followed by an 
incubation for 1 h with 10 nM [‘H]25-(OH)D, as substrate. Next, after a 
2 h wash the 25(OHID, metabolites were extracted and analyzed by 
HPLC. Data are expressed as fmol 24,25-(OH&D, formed kS.D. of at 
least two independent cultures. * P < 0.001 versus no addition of 
1,25-(OH&D, and forskolin or PMA; # P < 0.05 and ## P < 0.001 
calculated as significance of interaction between 1,25-(OH), D, and 
forskolin or PMA. 
affect basal as well as 1,25-(OH), D,-stimulated osteocal- 
tin production [39]. 
4. Discussion 
1,25-(OH),D, and PTH regulate osteoblast activity via 
close interactions. On basis of the present observation that 
PTH potentiates 1,25-(OH),D, action in osteoblasts and 
the previously reported inhibition of PTH-stimulated CAMP 
production by 1,25-(OH),D, [7,8] a negative feedback-loop 
at target cell level can be postulated. This mimics the 
well-known systemic feedback-loop in which PTH stimu- 
lates renal 1,25-(OH), D, synthesis whereas 1,25-(OH), D, 
inhibits PTH synthesis by the parathyroid glands. 
The currently observed interactions between 1,25- 
(OH),D, and PTH are logical from a physiological point 
of view. Within minutes a reduction in serum calcium is 
followed by a rise in serum PTH level. Subsequently, 
within hours, stimulation of renal 25-(OH)-D,- 1 a-hydrox- 
ylase by PTH occurs which eventually results in an in- 
creased serum 1,25-(OH),D, level [l]. Under these cir- 
cumstances also bone will first be exposed to increased 
PTH levels before increased 1,25-(OH),D, levels. The 
present results indicate that despite unchanged serum 1,25- 
(OH),D, levels already an enhancement of its action on 
bone cells to restore serum calcium levels could be 
achieved. The biological significance of 1,25-(OH),D, 
and PTH interaction is also supported by the observation 
that some hypoparathyroid patients are resistant to 1,25- 
(OH),D, for the treatment of hypocalcemia [20,21]. 
The analysis of the role of intracellular signal pathways 
demonstrated that in general activation of protein kinase A 
via increased CAMP production enhances the 1,25- 
(OH),D, action in osteoblasts whereas protein kinase C 
attenuates the 1,25-(OH),D, effects. Our data on interac- 
tions between CAMP and 1,25-(OH),D, are in line with 
recent findings that CAMP enhances the 1,25-(OH),D, 
action in lymphocytes and fibroblasts [40-431. However, 
target tissue/cell-specific interaction between 1,25- 
(OH),D, and PTH (CAMP, protein kinase C> is evident 
from comparison of the data obtained on renal 24-hydrox- 
ylase and our results. In the kidney PTH, via CAMP, 
reduces 1,25-(OH), D,-induced renal 24-hydroxylase activ- 
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Fig. 7. Effect of PTH and forskolin on 1,25-(OH),D,-stimulated osteo- 
calcin production by (A) MG-63 cells and (B) R&S i7/2.8 ceils. Cells 
were incubated for 24 h and next osteocalcin concentration in the medium 
was analyzed. The changes in cellular osteocalcin content of ROS 17/2.8 
cells were similar as the changes observed in the medium. The cellular 
osteocalcin content of MG-63 cells was below detection level. Within the 
24 h incubation period vitamin D did not change the proliferation. 
Expressed as Fg DNA/well the following DNA values were obtained 
after 24 h incubation, ROS 17/2.8 cells: Control: 49.3 IfI 1.7 and 10 nM 
1,25-(OH),D,: 52.6 + 1.8; MG-63 cells: Control: 113.8 +4.8 and 10 nM 
1,25-(OH)aD,: 1 17.7 *O. I (expressed as pg DNA/well). Data are pre- 
sented as ng osteocalcin kS.E.M. of 2-6 independent cultures. * 
P < 0.02 and * * P < 0.002 versus no addition of 1,25-(OH)zD, and 
PTH or forskolin; # P < 0.02 and ## P < 0.002 calculated as signifi- 
cance of interaction between 1,25-(OH),D, and PTH or forskolin. 
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ity as well as 24-hydroxylase mRNA expression [44,45] 
whereas activation of protein kinase C by phorbol esters 
potentiates 1,25-(OH),D,-induced renal 24-hydroxylase 
mRNA expression [46,47]. From the present study and 
previously reported data on the absence of effect of protein 
kinase C activation on 1,25-(OH),D,-stimulated responses 
in both renal and bone tissue [39,43-461 it is clear that 
CAMP and protein kinase C have opposite effects on 
1,25-(OH),D, action. The fact that PTH stimulates both 
CAMP production and protein kinase C activity [33,34] 
suggests that the PTH-activated CAMP pathway overrules 
the protein kinase C pathway. 
The present study demonstrates interactions in os- 
teoblasts between 1,25-(OH),D, and PTH when the two 
hormones are tested simultaneously. This is in contrast to a 
recent study on pretreatment of the cells with PTH. Pre- 
treatment with PTH resulted in up-regulation of the VDR 
and subsequently an enhanced 1,25-(OH),D, induction of 
24-hydroxylase mRNA expression [48]. It is, however, for 
the following reasons unlikely that the synergistic up-regu- 
lation of VDR is involved in the potentiation of 24-hydrox- 
ylase activity in UMR 106 and MG-63 cells and osteocal- 
tin production in ROS 17/2.8 cells. In UMR 106 cells 
both up-regulation of VDR and induction of 24-hydroxyl- 
ase activity are initiated simultaneously upon addition of 
both hormones. Moreover, in ROS 17/2.8 cells there is no 
synergistic up-regulation of VDR whereas 1,25-(OH), D, 
induction of osteocalcin synthesis is augmented by PTH, 
and finally, in MG-63 cells no up-regulation of VDR 
whereas stimulation of 24-hydroxylase activity is potenti- 
ated by PTH. Several mechanisms to account for the 
interaction between 1,25-(OH),D, and PTH can be put 
forward. Firstly, direct interaction at gene level: In the 
osteocalcin promoter both vitamin D response elements 
and consensus CAMP-regulatory elements have been iden- 
tified [49]. Secondly, phosphorylation of VDR: Both ho- 
mologous- and heterologous-induction of phosphorylation 
of the VDR have been shown to be important for transcrip- 
tional activation [50-521. The VDR can be phosphorylated 
at specific sites by CAMP-dependent protein kinase A, 
protein kinase C and casein kinase II [52-551. Thirdly, 
stabilization of mRNA: For osteocalcin mRNA it has been 
reported that parathyroid hormone increases its stability 
1561. Although it is conceivable that one or more of these 
mechanisms are involved in the interactions between 1,25- 
(OH),D, and PTH their exact role or the involvement of a 
yet unidentified process remains to be established. 
It is becoming evident that steroid and peptide regula- 
tors of cell function do not act independently. The analysis 
of the cross-talk between the signal transduction pathways 
of these two chemically distinct compounds is crucial for 
the understanding of their eventual biological response. 
Although limited, interactions between the CAMP pathway 
and the steroid hormone mechanism of action have been 
described in other systems [57-601. Even a complete 
change of function has been observed. In the presence of 
CAMP both the progesterone antagonist RU486 and the 
estrogen antagonist tamoxifen display agonist-like activi- 
ties [59-611. Most of these studies concern experiments 
with reporter constructs transfected into cells. The present 
study demonstrates coordinated regulation of endogenous 
cellular responses (i.e. not transfected reporter constructs) 
by hormones acting via an intracellular receptor or via a 
membrane bound receptor. 
Although PTH is active in all three cell lines tested 
(Figs. 1 and 5B, Fig. 7B), some of the observed interac- 
tions with 1,25-(OH),D, appeared to be partially cell line- 
and response-specific. Considering the osteoblast-differ- 
entiation scheme defined by Stein et al. 1621 the three 
osteoblastic cell lines used may represent different stages 
of osteoblast differentiation. UMR 106 resemble poorly 
differentiated osteoblasts as no basal and 1,25-(OH),D,- 
stimulated osteocalcin production is present. MG-63 cells 
may be representative for the intermediate-early differenti- 
ation phenotype: high collagen type I and low osteocalcin 
production levels, while on the basis of the high osteocal- 
tin levels the ROS 17/2.8 cells are fully differentiated 
osteoblasts. Therefore, the present observations suggest 
that interaction(s) between 1,25-(OH),D, and PTH are 
dependent on differentiation status of the osteoblast. Previ- 
ously it has been shown that the response to 1,25-(OH&D, 
is related to the proliferative and differentiated state of 
osteoblasts [63]. The observation by Chambers and Mc- 
Sheehy [64] that conditioned medium of UMR 106 cells is 
a potent stimulator of bone resorption whereas conditioned 
medium of ROS 17/2.8 cells hardly stimulate bone resorp 
tion is indicative for the fact that these cells indeed repre- 
sent osteoblasts with different functional roles, i.e. in- 
volved in regulation of bone resorption or in bone forma- 
tion. However, to address this aspect more specifically 
studies with a well defined osteoblast differentiation model 
are needed [62]. The different effects of PTH on 1,25- 
(OHlz D, induction of osteocalcin synthesis may be related 
to a species difference. An earlier study showed that 
CAMP enhances 1,25-(OH),D,-induction of osteocalcin 
mRNA expression in ROS 17/2.8 cells [65] but not in 
human bone cells derived from surgical specimens [66,67]. 
Together, the present study shows that 1,25-(OH),D, 
and PTH, two chemically distinct calciotropic hormones, 
act at cellular level in a coordinated manner to regulate 
osteoblast activity. This adds up to systemic interaction 
with respect to the mutual regulation of each others pro- 
duction and secretion. 
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